DK3455212T3 - Hæmmere af protease-aktiveret receptor-2 - Google Patents

Hæmmere af protease-aktiveret receptor-2 Download PDF

Info

Publication number
DK3455212T3
DK3455212T3 DK17725905.8T DK17725905T DK3455212T3 DK 3455212 T3 DK3455212 T3 DK 3455212T3 DK 17725905 T DK17725905 T DK 17725905T DK 3455212 T3 DK3455212 T3 DK 3455212T3
Authority
DK
Denmark
Prior art keywords
protease
inhibitors
activated receptor
receptor
activated
Prior art date
Application number
DK17725905.8T
Other languages
English (en)
Inventor
John Graham Cumming
Karl Henrik Edman
Hongming Chen
Roland Werner Burli
Shawn Donald Johnstone
Frank Xinhe Wu
Dean Gordon Brown
Giles Albert Brown
Benjamin Gerald Tehan
Barry John Teobald
Miles Stuart Congreve
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Application granted granted Critical
Publication of DK3455212T3 publication Critical patent/DK3455212T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK17725905.8T 2016-05-12 2017-05-11 Hæmmere af protease-aktiveret receptor-2 DK3455212T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662335496P 2016-05-12 2016-05-12
PCT/EP2017/061409 WO2017194716A1 (en) 2016-05-12 2017-05-11 Inhibitors of protease-activated receptor-2

Publications (1)

Publication Number Publication Date
DK3455212T3 true DK3455212T3 (da) 2022-03-28

Family

ID=58772863

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17725905.8T DK3455212T3 (da) 2016-05-12 2017-05-11 Hæmmere af protease-aktiveret receptor-2

Country Status (5)

Country Link
US (2) US10550089B2 (da)
EP (1) EP3455212B1 (da)
DK (1) DK3455212T3 (da)
ES (1) ES2909709T3 (da)
WO (1) WO2017194716A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017194716A1 (en) 2016-05-12 2017-11-16 Astrazeneca Ab Inhibitors of protease-activated receptor-2
US20240066027A1 (en) 2020-12-03 2024-02-29 Domain Therapeutics Novel par-2 inhibitors
KR20250057699A (ko) 2022-06-03 2025-04-29 도메인 테라퓨틱스 신규한 par-2 억제제
WO2025172573A1 (en) 2024-02-16 2025-08-21 Domain Therapeutics Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer
WO2025191185A1 (en) 2024-03-15 2025-09-18 Domain Therapeutics Azine-based compounds as par-2 inhibitors and therapeutic uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11209375A (ja) * 1998-01-23 1999-08-03 Nippon Bayer Agrochem Co Ltd 複素環置換アルコール誘導体及び農園芸用殺菌剤
GB9929674D0 (en) * 1999-12-15 2000-02-09 Novartis Res Found Protease-activated receptor (PAR) modulator assays
US20060104944A1 (en) * 2004-11-18 2006-05-18 Mousa Shaker A Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use
US7592362B2 (en) * 2006-01-19 2009-09-22 Pfizer Limited Substituted imidazoles
CA2637312A1 (en) * 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of substituted 2-imidazole of imidazoline derivatives
US20100041712A1 (en) * 2008-08-18 2010-02-18 Pfizer Inc. Substituted imidazole combinations
EP3351641A1 (en) * 2011-04-08 2018-07-25 Tufts Medical Center, Inc. Pepducin design and use
HK1223096A1 (zh) * 2013-09-25 2017-07-21 Vertex Pharmaceuticals Incorporated 用作par-2信號通路抑制劑的咪唑並噠嗪
WO2017083618A1 (en) * 2015-11-13 2017-05-18 Oasis Pharmaceuticals, LLC Protease-activated receptor-2 modulators
WO2017194716A1 (en) 2016-05-12 2017-11-16 Astrazeneca Ab Inhibitors of protease-activated receptor-2

Also Published As

Publication number Publication date
WO2017194716A1 (en) 2017-11-16
US20200140392A1 (en) 2020-05-07
US20190144394A1 (en) 2019-05-16
EP3455212A1 (en) 2019-03-20
US10550089B2 (en) 2020-02-04
ES2909709T3 (es) 2022-05-10
US10995072B2 (en) 2021-05-04
EP3455212B1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
IL263586A (en) Inhibitors of the menin-mll interaction
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
PL3657060T3 (pl) Zacisk
DK3463248T3 (da) Anordnnger til anvendelse af lægemiddelanordninger
LT3303334T (lt) Tirozinkinazės inhibitoriai
DK3442972T3 (da) Bromdomænehæmmere
EP3291773A4 (en) TEMPORARY INTERATRIAL SHUNTS
EP3415959A4 (en) ANTI REFLEX COATING
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
EP3210371C0 (en) CAMERA APPLICATION
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
EP3247317C0 (en) Stent
DK3365563T3 (da) Forbindelseskomponent
SI3347127T1 (sl) Naprava za prestavljanje
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS
UY4562S (es) Cámara
EP3378902A4 (en) ANTI REFLEX FILM
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
EP3413101A4 (en) ANTI REFLECTION FILM
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3076224T3 (da) Feltkartograf
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
EP3812637C0 (de) Spannschelle